- Trials with a EudraCT protocol (44,347)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (18,700)
44,347 result(s) found.
Displaying page 1,228 of 2,218.
EudraCT Number: 2008-007925-38 | Sponsor Protocol Number: HE 4/09 | Start Date*: 2009-04-07 | |||||||||||
Sponsor Name:Hellenic Cooperative Oncology Group | |||||||||||||
Full Title: STUDY OF THE mTOR INHIBITOR TEMSIROLIMUS (CCI-779) IN PATIENTS WITH CA125 ONLY RELAPSE OF OVARIAN CANCER A phase II study by the Hellenic Cooperative Oncology Group | |||||||||||||
Medical condition: Ovarian cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: GR (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002364-13 | Sponsor Protocol Number: M16VIB | Start Date*: 2018-01-23 | |||||||||||
Sponsor Name:Netherlands Cancer Institute- Antoni van Leeuwenhoek hospital (NKI-AVL) | |||||||||||||
Full Title: MoTriColor: A phase II study of vinorelbine in advanced BRAF-like colon cancer | |||||||||||||
Medical condition: colon carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) BE (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-006515-76 | Sponsor Protocol Number: REO 011 | Start Date*: 2007-01-08 | |||||||||||
Sponsor Name:Oncolytics Biotech Inc | |||||||||||||
Full Title: A Dose Targeted Phase I/II Study To Evaluate The Feasibility, Safety, And Biological Effects Of Intravenous Administration of A Wild-Type Reovirus (REOLYSIN®) in Combination With Paclitaxel and Car... | |||||||||||||
Medical condition: Advanced or metastatic solid tumours that are refractory to standard therapy or for which no curative standard therapy exists and for which paclitaxel plus carboplatin is appropriate palliative che... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-004314-15 | Sponsor Protocol Number: SP015 | Start Date*: 2016-11-16 | |||||||||||
Sponsor Name:SOTIO a.s. | |||||||||||||
Full Title: A phase I/II, single-arm clinical trial to evaluate the safety and immune activation of the combination of DCVAC/PCa, an active cellular immunotherapy, and ONCOS-102, an immune-priming adenovirus, ... | |||||||||||||
Medical condition: advanced metastatic castration-resistant prostate cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-002062-39 | Sponsor Protocol Number: AOUMeyer#1 | Start Date*: 2013-11-04 |
Sponsor Name:Azienda Ospedaliero-Universitaria Meyer | ||
Full Title: Safety and efficacy of propranolol eye drops in neonates with retinopathy of prematurity: a pilot study (DROP-ROP). | ||
Medical condition: The medical condition to be investigated is Retinopathy of Prematurity (ROP) | ||
Disease: | ||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | |
Trial protocol: IT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2018-002069-21 | Sponsor Protocol Number: D5180C00013 | Start Date*: 2018-10-23 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Phase 2, Randomized, Double-blind, Parallel Group, Placebo Controlled Study to Evaluate the Effect of Tezepelumab on Airway Inflammation in Adults with Inadequately Controlled Asthma on Inhaled C... | |||||||||||||
Medical condition: Severe Asthma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) GB (GB - no longer in EU/EEA) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-020423-51 | Sponsor Protocol Number: ETA0881X1-4718 | Start Date*: 2011-02-17 | |||||||||||
Sponsor Name:Asklepios Klinik Sankt Augustin | |||||||||||||
Full Title: Remission Induction by Etanercept in Enthesitis related Arthritis JIA-Patients (juvenile undifferentiated Spondylarthropathy) | |||||||||||||
Medical condition: Active enthesitis-related arthrtitis as a category of juvenile idiopathic arthritis (ERA-JIA) as determined by International League of Associations for Rheumatology (ILAR) criteria. | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-015516-18 | Sponsor Protocol Number: 001 | Start Date*: 2010-08-06 |
Sponsor Name:Univ.-Klinik für Augenheilkunde und Optometrie, Medizinische Universität Wien | ||
Full Title: Microstructural morphological changes of the macula after intravitreal microplasmin for non-surgical treatment of vitreomacular traction syndrome | ||
Medical condition: Vitreomacular traction syndrome (VMTS) is a distinct clinical entity characterized by an incomplete separation of the posterior vitreous surface from the retina with persistent posterior hyaloid ad... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-002771-33 | Sponsor Protocol Number: ATX201-207 | Start Date*: 2019-09-25 | |||||||||||
Sponsor Name:UNION therapeutics A/S | |||||||||||||
Full Title: A Randomized, Double-Blind, Parallel Group, Vehicle-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of Topical ATx201 OINTMENT in Adolescents and Adults with Mild to Moderate Atopic De... | |||||||||||||
Medical condition: Atopic Dermatitis | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) PL (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-003089-34 | Sponsor Protocol Number: HND-IM-011 | Start Date*: 2011-09-06 | |||||||||||||||||||||
Sponsor Name:Chr. Hansen A/S | |||||||||||||||||||||||
Full Title: The effect for Lactobacillus paracasei subsp. paracasei, L. casei 431® on immune response to influenza vaccination in healthy adult volunteers - a multi-center, randomized, placebo-controlled, par... | |||||||||||||||||||||||
Medical condition: effect of probiotics on the immune response to seasonal influenza vaccination in healthy adults | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2006-002190-49 | Sponsor Protocol Number: REO 008 | Start Date*: 2006-11-08 | |||||||||||
Sponsor Name:Oncolytics Biotech Inc | |||||||||||||
Full Title: A Multi-Centre Single-Arm Phase II Study To Evaluate The Biological Effects Of Intratumoral Administration of Wild-Type Reovirus (REOLYSIN®) in Combination with Low Dose Radiation in Patients With ... | |||||||||||||
Medical condition: Advanced or metastatic solid tumours that are refractory to standard therapy or for which no standard curative therapy exists | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-002588-14 | Sponsor Protocol Number: APOTEL-02 | Start Date*: 2014-09-22 | |||||||||||
Sponsor Name:UNI-PHARMA SA | |||||||||||||
Full Title: A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED PHASE IV CLINICAL STUDY OF THE EFFICACY AND SAFETY OF A NEW FORMULATION OF PARACETAMOL FOR THE MANAGEMENT OF FEVER OF INFECTIOUS ORIGIN | |||||||||||||
Medical condition: Fever due to infection of the upper respiratory tract, of the lower respiratory tract, acute pyelonephritis or of the skin and soft tissues. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-002178-35 | Sponsor Protocol Number: DC2014ELIX001 | Start Date*: 2014-08-06 |
Sponsor Name:VU University Medical Center | ||
Full Title: A phase 4, monocenter, randomized, open label, comparator-controlled, parallel-group, mechanistic intervention trial to assess the effect of 8-week treatment with the glucagon-like peptide-1 recept... | ||
Medical condition: Type 2 Diabetes Mellitus | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-003970-28 | Sponsor Protocol Number: VX18-561-101 | Start Date*: 2019-06-18 | |||||||||||
Sponsor Name:Vertex Pharmaceuticals Incorporated | |||||||||||||
Full Title: A Phase 2, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of VX-561 in Subjects Aged 18 Years and Older With Cystic Fibrosis | |||||||||||||
Medical condition: Cystic Fibrosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) BE (Completed) NL (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-002484-25 | Sponsor Protocol Number: TAK-935-2002(OV935) | Start Date*: 2019-04-29 |
Sponsor Name:Takeda Development Center Americas, Inc. | ||
Full Title: A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TAK-935 (OV935) AS AN ADJUNCTIVE THERAPY IN PEDIATRIC PATIENTS WITH ... | ||
Medical condition: Epileptic Encephalitis: Dravet and Lennox Gastuat syndrome (LGS) | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: PT (Completed) PL (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-004800-23 | Sponsor Protocol Number: RG-17-241 | Start Date*: 2018-06-12 | |||||||||||
Sponsor Name:University of Birmingham | |||||||||||||
Full Title: A comparison of reduced dose total body irradiation (TBI) and cyclophosphamide with fludarabine and melphalan reduced intensity conditioning in adults with acute lymphoblastic leukaemia (ALL) in co... | |||||||||||||
Medical condition: Acute Lymphoblastic Leukaemia (ALL) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002123-15 | Sponsor Protocol Number: GEICAM/2019-01 | Start Date*: 2020-06-15 | |||||||||||
Sponsor Name:GEICAM (Fundación Grupo Español de Investigación en Cáncer de Mama) | |||||||||||||
Full Title: Phase II, randomized, open-label, international, multicenter study to compare efficacy of standard chemotherapy vs. letrozole plus abemaciclib as neoadjuvant therapy in HR-positive/HER2-negative hi... | |||||||||||||
Medical condition: High/intermediate risk hormone receptor (HR) positive/human epidermal growth factor receptor 2 (HER2) negative breast cancer patients with indication of neoadjuvant therapy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-000851-42 | Sponsor Protocol Number: ID-084A201 | Start Date*: 2018-07-27 | |||||||||||
Sponsor Name:Idorsia Pharmaceuticals Ltd | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled, 12-week treatment study to evaluate the effect of ACT-774312 in subjects with bilateral nasal polyposis | |||||||||||||
Medical condition: Bilateral nasal polyposis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000998-72 | Sponsor Protocol Number: 4083-006 | Start Date*: 2019-01-22 | |||||||||||
Sponsor Name:Kyowa Kirin Co., Ltd. | |||||||||||||
Full Title: A Phase 2, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of an Anti-OX40 Monoclonal Antibody (KHK4083) in Subjects with Moderate to Severe Atopic Dermatitis | |||||||||||||
Medical condition: Moderate to Severe Atopic Dermatitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-020749-28 | Sponsor Protocol Number: GETNE-1002 | Start Date*: 2010-11-08 | |||||||||||
Sponsor Name:Grupo Español de Tumores Neuroendocrinos (GETNE) | |||||||||||||
Full Title: Ensayo clínico fase II, abierto, no controlado, multicéntrico de pazopanib en monoterapia para la determinación de actividad, seguridad y biomarcadores predictivos en pacientes con progresión de t... | |||||||||||||
Medical condition: Pacientes con progresión de tumores neuroendocrinos (NET) avanzados/metastásicos | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
